Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa in Prior Placebo HCV Patients
NCT02346721Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Primary completion
- Mar 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 12 weeks. Started Feb 2015; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02346721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346721.